The risk of hair loss in patients taking GLP-1 drugs, while low, is higher than with other diabetes drugs, new studies suggest.

Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and ...

Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare ...

Eli Lilly LLY is a dominant player in the cardiometabolic market, backed by a strong and expanding GLP-1 portfolio. Its GLP-1 lineup includes Mounjaro and Zepbound (tirzepatide injections) for type II ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Eli Lilly (NYSE: LLY) has spent the past two years reinvesting the cash flow from its spectacularly successful GLP-1 drug into building out its pipeline, and it just made a diversification play unlike ...

Eli Lilly and Co. LLY on Thursday reported topline results from two pivotal Phase 3 trials for its investigational ...

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of ...

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

A $2.5 billion settlement with Amazon Prime is in the works, a pharmaceutical company accuses another of false advertising ...